JPH02178207A - Dermal cosmetic - Google Patents
Dermal cosmeticInfo
- Publication number
- JPH02178207A JPH02178207A JP33378188A JP33378188A JPH02178207A JP H02178207 A JPH02178207 A JP H02178207A JP 33378188 A JP33378188 A JP 33378188A JP 33378188 A JP33378188 A JP 33378188A JP H02178207 A JPH02178207 A JP H02178207A
- Authority
- JP
- Japan
- Prior art keywords
- skin
- effect
- dermal
- water
- peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002537 cosmetic Substances 0.000 title claims abstract description 19
- 230000002500 effect on skin Effects 0.000 title abstract description 9
- 108010089975 arginyl-glycyl-aspartyl-serine Proteins 0.000 claims abstract description 18
- NNRFRJQMBSBXGO-CIUDSAMLSA-N (3s)-3-[[2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]-4-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-oxobutanoic acid Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O NNRFRJQMBSBXGO-CIUDSAMLSA-N 0.000 claims abstract description 17
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 claims abstract description 16
- 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 claims abstract description 16
- 229920003169 water-soluble polymer Polymers 0.000 claims abstract description 13
- 230000000694 effects Effects 0.000 abstract description 29
- 235000010418 carrageenan Nutrition 0.000 abstract description 3
- 239000000679 carrageenan Substances 0.000 abstract description 3
- 229920001525 carrageenan Polymers 0.000 abstract description 3
- 229940113118 carrageenan Drugs 0.000 abstract description 3
- 230000003405 preventing effect Effects 0.000 abstract description 3
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 abstract description 3
- 230000007246 mechanism Effects 0.000 abstract description 2
- 230000002708 enhancing effect Effects 0.000 abstract 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 abstract 1
- 235000003704 aspartic acid Nutrition 0.000 abstract 1
- DWBZEJHQQIURML-UHFFFAOYSA-N aspartyl-serine Chemical compound OC(=O)CC(N)C(=O)NC(CO)C(O)=O DWBZEJHQQIURML-UHFFFAOYSA-N 0.000 abstract 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 64
- 239000000203 mixture Substances 0.000 description 25
- 238000012360 testing method Methods 0.000 description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 108090000765 processed proteins & peptides Proteins 0.000 description 13
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 12
- 230000006872 improvement Effects 0.000 description 10
- 239000008213 purified water Substances 0.000 description 9
- 239000002994 raw material Substances 0.000 description 9
- 239000006210 lotion Substances 0.000 description 8
- 206010013786 Dry skin Diseases 0.000 description 7
- 230000000052 comparative effect Effects 0.000 description 7
- 230000037336 dry skin Effects 0.000 description 7
- 239000004615 ingredient Substances 0.000 description 7
- 239000012071 phase Substances 0.000 description 7
- 210000000434 stratum corneum Anatomy 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 102000008186 Collagen Human genes 0.000 description 5
- 108010035532 Collagen Proteins 0.000 description 5
- 108010076876 Keratins Proteins 0.000 description 5
- 102000011782 Keratins Human genes 0.000 description 5
- 239000008346 aqueous phase Substances 0.000 description 5
- 229920001436 collagen Polymers 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000011347 resin Substances 0.000 description 5
- 229920005989 resin Polymers 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 4
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 4
- 230000014759 maintenance of location Effects 0.000 description 4
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- IYMAXBFPHPZYIK-UHFFFAOYSA-N 2-[[2-[[2-azaniumyl-5-(diaminomethylideneazaniumyl)pentanoyl]amino]acetyl]amino]butanedioate Chemical compound NC(N)=NCCCC(N)C(=O)NCC(=O)NC(CC(O)=O)C(O)=O IYMAXBFPHPZYIK-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 238000009739 binding Methods 0.000 description 3
- 108010015046 cell aggregation factors Proteins 0.000 description 3
- 210000000736 corneocyte Anatomy 0.000 description 3
- 230000003020 moisturizing effect Effects 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 230000009993 protective function Effects 0.000 description 3
- 230000009759 skin aging Effects 0.000 description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 230000021164 cell adhesion Effects 0.000 description 2
- 229960000541 cetyl alcohol Drugs 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
- 229960002216 methylparaben Drugs 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 230000036620 skin dryness Effects 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- WGTYBPLFGIVFAS-UHFFFAOYSA-M tetramethylammonium hydroxide Chemical compound [OH-].C[N+](C)(C)C WGTYBPLFGIVFAS-UHFFFAOYSA-M 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- PAFJZWHXMSQJKV-UQZRNVAESA-N (3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol;octadecanoic acid Chemical compound OC[C@@H](O)C1OC[C@H](O)[C@H]1O.OC[C@@H](O)C1OC[C@H](O)[C@H]1O.OC[C@@H](O)C1OC[C@H](O)[C@H]1O.CCCCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O PAFJZWHXMSQJKV-UQZRNVAESA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- FLPJVCMIKUWSDR-UHFFFAOYSA-N 2-(4-formylphenoxy)acetamide Chemical compound NC(=O)COC1=CC=C(C=O)C=C1 FLPJVCMIKUWSDR-UHFFFAOYSA-N 0.000 description 1
- BGRXBNZMPMGLQI-UHFFFAOYSA-N 2-octyldodecyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCC(CCCCCCCC)CCCCCCCCCC BGRXBNZMPMGLQI-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- -1 BOC-amino Chemical class 0.000 description 1
- 108010075254 C-Peptide Proteins 0.000 description 1
- 102000009268 Collagen Receptors Human genes 0.000 description 1
- 108010048623 Collagen Receptors Proteins 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- SCCPDJAQCXWPTF-VKHMYHEASA-N Gly-Asp Chemical compound NCC(=O)N[C@H](C(O)=O)CC(O)=O SCCPDJAQCXWPTF-VKHMYHEASA-N 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 108010042918 Integrin alpha5beta1 Proteins 0.000 description 1
- 102000007547 Laminin Human genes 0.000 description 1
- 108010085895 Laminin Proteins 0.000 description 1
- 229920000057 Mannan Polymers 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 206010039792 Seborrhoea Diseases 0.000 description 1
- 241000978776 Senegalia senegal Species 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000019552 anatomical structure morphogenesis Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 210000000270 basal cell Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 229940074979 cetyl palmitate Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- 229960005188 collagen Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000008278 cosmetic cream Substances 0.000 description 1
- 239000008271 cosmetic emulsion Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000004920 epithelial cell of skin Anatomy 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000004299 exfoliation Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- PXDJXZJSCPSGGI-UHFFFAOYSA-N hexadecanoic acid hexadecyl ester Natural products CCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC PXDJXZJSCPSGGI-UHFFFAOYSA-N 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000003475 lamination Methods 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229940073665 octyldodecyl myristate Drugs 0.000 description 1
- 230000037312 oily skin Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- QSHGUCSTWRSQAF-FJSLEGQWSA-N s-peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C1=CC=C(OS(O)(=O)=O)C=C1 QSHGUCSTWRSQAF-FJSLEGQWSA-N 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 239000002884 skin cream Substances 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 230000005808 skin problem Effects 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 238000003746 solid phase reaction Methods 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Abstract
Description
【発明の詳細な説明】
［産業上の利用分野］
本発明は、トリペプチドＡｒ ｇ−Ｇ ｌ ｙ−Ａｓｐ
又はテトラペプチドＡｒ ｇ−Ｇ ｌ ｙ−Ａｓ ｐ
−Ｓｅｒと水溶性高分子を含有してなる皮膚老化防止効
果（荒肌改善効果、保湿効果等）と美肌効果に優れた皮
膚化粧料に関する。Detailed Description of the Invention [Industrial Field of Application] The present invention provides tripeptide Ar g-G ly-Asp
or tetrapeptide Ar g-G ly-Asp
The present invention relates to a skin cosmetic containing Ser and a water-soluble polymer and having excellent skin aging prevention effects (improving rough skin effects, moisturizing effects, etc.) and skin beautifying effects.
〔従来の技術及び発明が解決しようとする課題〕皮膚は
、個体を外的環境から守る役割、即ち異物の侵入を防ぎ
、体液の喪失を防ぐ役割を果たしている。皮膚の水分は
、真皮から表皮の基底細胞層、更に角質層へと外層に向
うにつれて減少する水分含量の勾配が存在し、常に皮膚
内部から外層部へ移動し、角質層を通じて外部へ蒸散し
ている。[Prior Art and Problems to be Solved by the Invention] The skin plays the role of protecting an individual from the external environment, that is, preventing the invasion of foreign substances and preventing loss of body fluids. There is a water content gradient in the skin that decreases from the dermis to the basal cell layer of the epidermis and then to the stratum corneum, and it constantly moves from the inside of the skin to the outer layer and transpires to the outside through the stratum corneum. There is.
この水分蒸散は主に角質層の緻密な細胞組織からなる防
御機能により制御されている。老化した皮膚や非常に乾
燥した皮膚においては、皮膚表面が乾燥して滑らかさが
なく、角質細胞の剥離現象や荒れ肌状態になることが認
められている。このような場合、皮膚の水分保持機能が
低下していることが認めらでいれる。即ち、角質層の防
御機能による通常の制御限界を超えた状態にあるか、あ
るいは防御機能が衰えていることに由来するものである
。This water evaporation is mainly controlled by the protective function of the dense cell tissue of the stratum corneum. It has been observed that in aged skin or very dry skin, the skin surface becomes dry and lacks smoothness, leading to exfoliation of corneocytes and rough skin. In such cases, it is recognized that the skin's ability to retain moisture has decreased. In other words, it is caused by the condition exceeding the normal control limit of the protective function of the stratum corneum, or by the weakening of the protective function.
このような皮膚の問題点を解決する方法として皮膚表面
の角質層及び層板顆粒の組織を緻密化し、その防ＩＩＩ
機能を賦活することができれば、これによって皮膚の水
分保持機能が亢進され、皮膚は健常な状態に保持される
と共に、乾燥皮膚の改善ないしは修復が可能となると考
えられる。しかし、実際的に皮膚表面の状態を改善し、
老化皮膚、乾燥度Ｊ５を真に改善するような皮膚化粧料
はなく、適当な水分と油分を与える親水性の皮膚保湿剤
と油性の皮膚柔軟剤を皮膚化粧料に配合することが行わ
れている。いずれの成分も皮膚老化防止効果や美肌効果
を発揮するには至らなかった。As a way to solve these skin problems, the structure of the stratum corneum and lamellar granules on the skin surface is densified, and its prevention III
If this function can be activated, it is thought that the water retention function of the skin will be enhanced, the skin will be maintained in a healthy state, and it will be possible to improve or repair dry skin. However, it actually improves the condition of the skin surface,
There are no skin cosmetics that can truly improve aging skin and dryness level J5, and it is common practice to incorporate hydrophilic skin moisturizers and oily skin softeners into skin cosmetics to provide appropriate moisture and oil content. There is. None of the ingredients exhibited skin aging prevention effects or skin beautification effects.
また、ヒアルロン酸を始めとする酸性ムコ多糖類が、特
公昭３３−５００号、特開昭５１−１１１７８号、特開
昭５４−５２７３３号公報に見られるように保湿剤とし
て皮膚化粧料の成分として応用されているが、これらの
成分単独では皮膚の表面の水分量を調節するのみであり
、皮膚内部の水分保持機能を冗進し、美肌効果を発現す
るまでには至らなかった。In addition, acidic mucopolysaccharides such as hyaluronic acid are used as moisturizing agents in skin cosmetics, as shown in Japanese Patent Publication No. 33-500, Japanese Patent Application Laid-open No. 11178-1981, and Japanese Patent Application Laid-open No. 52733-1983. However, these ingredients alone only adjust the amount of moisture on the surface of the skin, but have not been able to enhance the moisture retention function within the skin and produce skin beautification effects.
本発明は、荒肌改善効果、保湿効果等の皮膚老化防止効
果と美肌効果に優れた皮膚化粧料を提供することを目的
としている。An object of the present invention is to provide a skin cosmetic that is excellent in skin aging prevention effects such as rough skin improvement effects and moisturizing effects, and skin beautification effects.
そこで、本発明者等は、上述の考え方に基づき、皮膚の
最外層である角質層の生化学的な生成メカニズム構成成
分について、鋭意研究した結果、トリペプチドであるア
ルギニルグリシルアスパラギン酸（Ａｒ ｇ−Ｇ Ｉ
ｙ−Ａｓ ｐ、以下ＲＣ，Ｄペプチドと略記する）また
はテトラペプチドであるアルギニルグリシルアスパルチ
ルセリン（ＡｒｇＧｌｙ−Ａｓｐ−Ｓｅｒ、以下ＲＧＤ
Ｓペプチドと略記する）と後記特定の水溶性高分子を含
有してなる皮膚化粧料は、老化皮膚や乾燥皮膚に適用し
た時に、皮膚の表面及び皮膚の最外層である角質層に直
接的に作用し、それらの表面構造を緻密化することによ
り、乾燥皮膚を改善し、水分保持機能を高め、皮膚の保
質性を改善する。更に、柔軟性、弾力性を与える美肌効
果を存することを見出し本発明を完成するに至った。Therefore, based on the above-mentioned idea, the present inventors conducted intensive research on the components of the biochemical production mechanism of the stratum corneum, which is the outermost layer of the skin. g-G I
y-Asp, hereinafter abbreviated as RC,D peptide) or the tetrapeptide arginylglycylaspartylserine (ArgGly-Asp-Ser, hereinafter RGD)
When applied to aging skin or dry skin, skin cosmetics containing a specific water-soluble polymer (abbreviated as S-peptide) and the specific water-soluble polymer described below directly affect the surface of the skin and the stratum corneum, which is the outermost layer of the skin. By densifying their surface structure, they improve dry skin, increase moisture retention, and improve skin retention. Furthermore, they discovered that it has a beautifying effect on the skin by imparting flexibility and elasticity, leading to the completion of the present invention.
本発明は、トリペプチドＡｒ ｇ−Ｇ ｌ ｙ−Ａｓ
ｐ又はテトラペプチドＡｒｇ−Ｇｌ ｙ−ＡＳｐ −Ｓ
ｅｒと水溶性高分子を含有してなる皮膚化粧料である。The present invention provides tripeptide Arg-Gly-As
p or tetrapeptide Arg-Gly-ASp-S
It is a skin cosmetic containing er and a water-soluble polymer.
本発明に用いるＲＧＤペプチドまたはＲＧＤＳペプチド
は細胞接着因子であるコラーゲン、フィブロネクチン、
ラミニン等の蛋白質の細胞に対する結合部位であり、こ
れらのペプチドを介して、種々の細胞に対して接着性を
示すことが、証明された（Ｍ、Ｄ、 ビニールシュバ
ンカー、Ｅ、ルーズシティ−。ネイチャー、３０９巻、
３０頁。The RGD peptide or RGDS peptide used in the present invention is a cell adhesion factor such as collagen, fibronectin,
It has been demonstrated that this is the binding site for proteins such as laminin to cells, and that these peptides exhibit adhesion to various cells (M, D, Vinylschbanker, E, Loose City). Nature, vol. 309,
30 pages.
１９８４年）。細胞側にはこれらのペプチドを認識する
レセプターが存在し、分子１１４万のフィブロネクチン
レセプター、分子量２５万、７万。(1984). There are receptors on the cell side that recognize these peptides, and the fibronectin receptor has a molecular weight of 1,140,000 and a molecular weight of 250,000 and 70,000, respectively.
３万の分子からなるコラーゲンレセプターの存在も判明
してきている。細胞接着因子は、種々の細胞に親和性を
示し、細胞の接着、伸展、増殖１分化、移動などの基本
的な作用に関与し、更に皮膚上皮細胞の形態形成にも関
与する。また、血液凝固反応や創傷治癒作用にも関与す
る。従って細胞接着因子の結合部位であるこれらのペプ
チドを使用するとこれらの細胞に対して、細胞接着因子
がそれ以上の作用が期待できる訳である。The existence of collagen receptors, which consist of 30,000 molecules, has also been discovered. Cell adhesion factors exhibit affinity for various cells and are involved in basic functions such as cell adhesion, spreading, proliferation, differentiation, and migration, and are also involved in the morphogenesis of skin epithelial cells. It is also involved in blood coagulation reactions and wound healing effects. Therefore, when these peptides, which are binding sites for cell adhesion factors, are used, it is expected that the cell adhesion factors will have a greater effect on these cells.
ＲＧＤまたはＲＧＤＳペプチドは、主に皮膚最外層に存
在する角質細胞に対して高い親和性を示し、角質細胞同
士の接着性を高め、表面構造を緻密化し、乾燥皮膚の改
善、水分保持ａ能の充進。RGD or RGDS peptides show a high affinity for corneocytes that mainly exist in the outermost layer of the skin, increase the adhesion between corneocytes, make the surface structure denser, improve dry skin, and improve water retention capacity. Advancement.
皮膚の保質性の改善を行い、更に皮膚に柔軟性。Improves skin retention and makes the skin more flexible.
弾力性を与える美肌効果を発揮する。It has a beautifying effect that gives elasticity to the skin.
本発明に用いるＲＧＤまたはＲＧＤＳペプチドは、通常
のべ・ブチド合成法である液相反応や固相反応により、
出発物質であるアミノ酸から順次ペプチド鎖を繋ぐこと
により合成でき、最後に保護基を除去することにより得
られる。The RGD or RGDS peptide used in the present invention can be produced by liquid-phase reaction or solid-phase reaction, which is the usual be-butide synthesis method.
It can be synthesized by sequentially connecting peptide chains from amino acids as starting materials, and is finally obtained by removing the protecting group.
本発明に用いる水溶性高分子は、デキストリン、サイク
ロデキストリン、デンプン カルボキシメチルセルロー
ス、ヒドロキシメチルセルロース。The water-soluble polymers used in the present invention include dextrin, cyclodextrin, starch, carboxymethylcellulose, and hydroxymethylcellulose.
ポリビニルピロリドン５ポリビニルアルコール。Polyvinylpyrrolidone 5 polyvinyl alcohol.
ペクチン、マンナン、アラビアゴム、ゼラチン。Pectin, mannan, gum arabic, gelatin.
可溶性コラーゲン、アルギン酸塩、キサンタンガム、カ
ラギーナン、ヒアルロン酸、コン１−ロイチン硫酸等が
適当であり、ＲＧＤまたはＲＣＤＳペプチドと組み合わ
せて皮膚化粧料に配合した場合、それぞれ単独に使用す
るよりも一層皮＋ａに対する親和性が向上し、優れた荒
れ肌改善効果、美肌効果が得られる。Soluble collagen, alginate, xanthan gum, carrageenan, hyaluronic acid, con-1-leucine sulfate, etc. are suitable, and when combined with RGD or RCDS peptide in skin cosmetics, they are more effective against skin + a than when used alone. The affinity is improved, and excellent effects on improving rough skin and beautifying the skin can be obtained.
本発明の皮膚化粧料は、上記ＲＧＤまたはＲＧＤＳペプ
チドと水溶性高分子を用い、通常の化粧料と同様にして
製造することができる。例えば、精製水及びアルコール
にＲＯＤまたはＲＧＤＳペプチドと水溶性高分子を均一
に混合することによりスキンローションを得ることがで
きる。また、油性物質や乳化剤を組み合わせることによ
り化粧用乳液や化粧用クリームを得ることができる。勿
論、上記化粧料には、必要に応じて着色剤、防腐剤、紫
外線吸収剤、酸化防止剤などの添加物を適宜配合するこ
とができる。The skin cosmetic of the present invention can be produced in the same manner as ordinary cosmetics using the RGD or RGDS peptide and water-soluble polymer. For example, a skin lotion can be obtained by uniformly mixing ROD or RGDS peptide and a water-soluble polymer in purified water and alcohol. Cosmetic emulsions and cosmetic creams can also be obtained by combining oily substances and emulsifiers. Of course, additives such as colorants, preservatives, ultraviolet absorbers, and antioxidants can be appropriately blended into the above cosmetics as required.
本発明の化粧料において、ＲＧＤまたはＲＧＤＳペプチ
ドの配合量は、０．０００１重量％（以下ｗｔ％と略記
する）から１． Ｏｗ ｔ％となるように設定すること
が好適である。即ち、０．０００１ｗｔ％未満では酵素
の働きが充分でなく、１．０ ｗ ｔ％を超えてもその
増加分に見合った効果の向上はなく、皮膚刺激が強くな
るなどの傾向が認められる。In the cosmetics of the present invention, the amount of RGD or RGDS peptide is 0.0001% by weight (hereinafter abbreviated as wt%) to 1.0% by weight. It is preferable to set it to Ow t%. That is, if the content is less than 0.0001 wt%, the enzyme does not function sufficiently, and if it exceeds 1.0 wt%, there is no improvement in the effect commensurate with the increase, and there is a tendency for skin irritation to become stronger.
本発明の化粧料において、水溶性高分子の配合量は、０
．００１ｗＬ％から５． Ｏｗ ｔ％となるように設定
することが好適である。即ち、０．００１ｗｔ％未満で
は酵素の働きが充分でなく、５．０ ｗ Ｌ％を超えて
もその増加分に見合った効果の向上はなく、べとつき感
が強くなるなどの傾向が認められる。In the cosmetic of the present invention, the amount of water-soluble polymer blended is 0.
．． 001wL% to 5. It is preferable to set it to Ow t%. That is, if the content is less than 0.001 wt%, the enzyme does not function sufficiently, and if it exceeds 5.0 wL%, there is no improvement in the effect commensurate with the increase, and there is a tendency for the sticky feeling to become stronger.
次に、この発明を実施例にもとづいて説明する。 Next, the present invention will be explained based on examples.
面、実施例に示す荒肌改善効果試験、角質改善効果試験
、実用試験、経口安定性試験はつぎのようにして行った
。The rough skin improvement effect test, keratin improvement effect test, practical test, and oral stability test shown in Examples were conducted as follows.
（荒肌改善効果試験）
荒れ肌、乾燥皮膚を訴える中高年被験者２０名の下脚を
対象として４週間続塗布効果を調べた。(Rough skin improvement effect test) The effect of continuous application for 4 weeks was investigated on the lower legs of 20 middle-aged and elderly subjects who complained of rough and dry skin.
被験者の左側下脚試験部位に１０１回約１ｇの試料を塗
布し、試験開始前及び終了後の皮膚の状態を下記の判定
基準により判定した。右側下層は試料を塗布せず対照と
した。Approximately 1 g of the sample was applied to the test site of the left lower leg of the subject 101 times, and the condition of the skin before and after the test was judged according to the following criteria. The lower layer on the right side was used as a control without applying any sample.
皮膚乾燥度の判定基準
：正常
± ：軽微乾燥、落屑なし
十 二乾燥、落屑軽度
十＋：乾燥、落屑中等度
＋＋＋：乾燥、落屑顕著
４：大スケール顕著
試験前後の試験部位と対照部位の判定結果を比較し、皮
膚乾燥度が２段階以上改善された場合（例えば、＋→−
１＋＋→±）を有効、１段階改善された場合をやや有効
、変化がなかった場合を無効とした。試験結果は有効、
やや有効となった被験者の人数で示した。Judgment criteria for skin dryness: Normal ±: Slight dryness, no flaking 12 Dryness, mild flaking 10+: Dryness, moderate flaking +++: Dryness, marked flaking 4: Large-scale noticeable Judgment of test and control areas before and after testing Compare the results and if the skin dryness has improved by two or more levels (for example, +→-
1++→±) was considered valid, a one-step improvement was considered somewhat effective, and no change was considered invalid. Test results are valid,
It is shown by the number of subjects who were somewhat effective.
（角質改善効果試験）
前述の荒肌改善効果試験開始前後の被験者皮膚にメンデ
ィングテープにチバン製）を接着し、これを剥離した時
テープに付着した角質細胞の状態を走査型電子顕微鏡に
よって詳細に調べた。そして、下記の基準により皮膚角
質細胞抗層離性を解析し、角質改善効果を求めた。(Test on the effect of improving keratin) A mending tape (manufactured by Chiban) was adhered to the subject's skin before and after the start of the above-mentioned rough skin improvement effect test, and when the tape was peeled off, the state of the keratinocytes attached to the tape was examined in detail using a scanning electron microscope. I looked into it. Then, the skin keratinocyte anti-lamination property was analyzed according to the following criteria, and the keratin improving effect was determined.
角質改善効果の判定基準
評価点１ニスケールを認めず
２：小スケール点在
３：小〜中スケール顕著
評価は、４週間連続塗布後の試験部位の評価点と対照部
位のそれとの差が２点以上の場合を有効、１点の場合を
やや有効、０点の場合を無効とした。Judgment criteria for keratin improving effect Evaluation points: 1 No scale observed 2: Small scales dotted 3: Small to medium scale noticeable Evaluation is based on the difference of 2 points between the evaluation score of the test area and that of the control area after 4 weeks of continuous application. Cases above were considered valid, cases of 1 point were considered somewhat valid, and cases of 0 points were considered invalid.
判定結果は、有効あるいはやや有効と回答した被験者の
人数で示した。The judgment results were expressed as the number of subjects who answered that the test was effective or somewhat effective.
（実用試験）
荒れ肌、小皺、乾燥肌等を訴える女子被験者（３５から
５５才）２０人に試料を１日朝タ２回連続３ケ月間塗布
し、その直後の下記項目について評価を行った。(Practical Test) Samples were applied to 20 female subjects (35 to 55 years old) who complained of rough skin, fine wrinkles, dry skin, etc. twice a day in the morning for three consecutive months, and the following items were evaluated immediately thereafter.
評価項目
湿潤性：皮膚に潤いが生じたと答えた人数平滑性：皮膚
が滑らかになったと答えた人数弾力性：皮膚に張りが生
じたと感じた人数（経口安定性試験）
試料を密封、遮光の条件下、４５°Ｃの恒温槽に３ケ月
間放置した後、色と匂いの変化の有無を観察した。Evaluation items: Wettability: Number of people who said their skin felt moisturized Smoothness: Number of people who said their skin became smooth Elasticity: Number of people who felt their skin became taut (Oral stability test) After being left in a constant temperature bath at 45°C for 3 months under these conditions, the presence or absence of changes in color and odor was observed.
実施例１
メリフィールドの開発したペプチド固相合成法に基づい
て、ＲＯＤペプチドを合成した。Example 1 ROD peptide was synthesized based on the peptide solid phase synthesis method developed by Merrifield.
出発物質として４級−ブチルオキシカルボニル−アスパ
ラギン酸ベンジルエステル（ＢＯＣ−Ａｓ ｐ （Ｂ
ｚ ｌ ） ） ３２．３ ｇを１００ｍのメタノール
に熔解し、１６０ｄの０．６２ Ｎテトラメチルアンモ
ニウムヒドロキシド／メタノール溶液とともにフラスコ
に入れ、減圧！縮する０次に５００Ｍ１！ジメチルホル
ムアミド（ＤＭＦ）に溶解し、５０ｇのクロロメチル樹
脂を加えて１４時間室温で反応させる。樹脂をガラスフ
ィルター上に取り、ＤＭＦ、メタノール、水、メタノー
ルの順によく洗い、乾燥し、ＢＯＣ−Ａｓ ｐ （Ｂｚ
Ｉ）樹脂５８゜３ｇを得た。Quaternary-butyloxycarbonyl-aspartic acid benzyl ester (BOC-As p (B
z l ) ) 32.3 g was dissolved in 100 m of methanol, put into a flask with 160 d of 0.62 N tetramethylammonium hydroxide/methanol solution, and the pressure was reduced! 500M1 shrinks to zero order! Dissolve in dimethylformamide (DMF), add 50g of chloromethyl resin, and react at room temperature for 14 hours. The resin was placed on a glass filter, thoroughly washed in the order of DMF, methanol, water, and methanol, dried, and then washed with BOC-As p (Bz
I) 58.3 g of resin was obtained.
次に、チャンらの方法（ジャーナル・オブ・オーガニフ
ク・ケミストリー ４１巻、３２５５頁、１９７６年）
によりＢＯＣ−アミノ酸を延長した。Next, the method of Chan et al. (Journal of Organic Chemistry, Vol. 41, p. 3255, 1976)
The BOC-amino acids were extended by
即ち、ＢＯＣ−Ａｓ ｐ （Ｂ ｚ Ｉ）樹脂５０．０
ｇを塩化メチレンで洗った後、３３％トリフルオロ酢
酸（ＴＦＡ）でＢＯＣ基を除去した後、１０％トリエチ
ルアミンにより中和操作を行い、塩化メチレン５００ｄ
に？容解したＢＯＣ−Ｇｌｙ２５ｇを添加し、ジシクロ
へキシルカルボジイミド３０ｇを添加して結合反応を行
った。最後に塩化メチレン、ＤＭＦ、メタノールにより
順次洗浄した。更に、同様の方法によりＢＯＣＡｒ ｇ
ＣＮ０ｔ ）を結合させ、ＢＯＣＡｒ ｇ （Ｎｏｔ
）Ｇｌｙ−Ａｓｐ （Ｂｚ １）−樹脂を調製した。That is, BOC-As p (B z I) resin 50.0
After washing g with methylene chloride, the BOC group was removed with 33% trifluoroacetic acid (TFA), and neutralization was performed with 10% triethylamine.
To? 25 g of dissolved BOC-Gly was added, and 30 g of dicyclohexylcarbodiimide was added to perform a binding reaction. Finally, it was washed successively with methylene chloride, DMF, and methanol. Furthermore, BOCAr g
CN0t ) and BOCAr g (Not
) Gly-Asp (Bz 1)-resin was prepared.
最後に、メリフィールドの方法（バイオケミカル・プレ
バレージョン、１２巻、９８頁、１９６８年）により臭
化水素ガス／ＴＦＡを用いて、ペプチドの各保護基を除
去した。更に、本ペプチドを充分洗浄した後、凍結乾燥
を行い、目的とするＲＧＤペプチド３ ］、 ４ ｇを
得た。Finally, each protecting group of the peptide was removed using hydrogen bromide gas/TFA according to the method of Merrifield (Biochemical Prevalence, Vol. 12, p. 98, 1968). Furthermore, this peptide was thoroughly washed and then freeze-dried to obtain 4 g of the target RGD peptide 3].
上記の方法により得たＲＧＤペプチドを用い、下記のよ
うな原料組成にしてそれらの成分を均一に混合すること
によりスキンローションを得た。Using the RGD peptide obtained by the above method, a skin lotion was obtained by uniformly mixing the ingredients in the following raw material composition.
組成 配合量（ｗｔ％）ＲＧＤペプ
チド ０．０２
カラギーナン １．００
精製水 総量を１００％とする残量い、下記のよ
うな原料組成にしてこれらの成分を均一に混合すること
によりスキンローションを得た。Composition Blend amount (wt%) RGD peptide 0.02 Carrageenan 1.00 Purified water With the remaining amount taking the total amount as 100%, skin lotion was obtained by uniformly mixing these ingredients with the following raw material composition. Ta.
組成 配合量（ｗＬ％）ＲＧＤペ
プチド ０．２
可溶性コラーゲン ２．０
精製水 総量を１００％とする残量実施例２
実施例１と同様の製法により得たＲＧＤＳペプチドを用
い、下記のような原料組成にしてこれらの成分を均一に
混合することによりスキンローションを得た。Composition Amount (wL%) RGD peptide 0.2 Soluble collagen 2.0 Purified water Remaining amount when the total amount is 100% Example 2 Using the RGDS peptide obtained by the same manufacturing method as Example 1, the following raw materials were prepared. A skin lotion was obtained by uniformly mixing these components.
組成 配合量（ｗｔ％）ＲＣ；Ｄ
Ｓペプチド ０．００５アルギン酸ナトリウム
１．０００
精製水 総量を１００％とする残量実施例４
実施例２と同様にして得たＲＧＤＳペプチドを用い、下
記のような原料組成にしてこれらの成分を均一に混合す
ることによりスキンローションを得た。Composition Blend amount (wt%) RC; D
S Peptide 0.005 Sodium Alginate
1.000 Purified water Remaining amount to make the total amount 100% Example 4 Using the RGDS peptide obtained in the same manner as in Example 2, a skin lotion was made by uniformly mixing these ingredients with the following raw material composition. I got it.
組成 配合Ｎ（ｗｔ％）ＲＧＤＳ
ペプチド ０．１
ヒアルロン酸ナトリウム ０．５
精製氷 総量を１００％とする残量実施例３
実施例１と同様にして得たＲＧＤペプチドを用実施例５
実施例１と同様にして得たＲＧＤペプチドを用い、下記
のような原料組成にして油相と水相を調製した。そして
、８０ ’Ｃに加熱した油相に同じく８０°Ｃに加熱し
た水相を加えて、均一に撹拌しながら速やかに冷却しス
キンミルクを得た。Composition Mixture N (wt%) RGDS
Peptide 0.1 Sodium hyaluronate 0.5 Purified ice Remaining amount to make the total amount 100% Example 3 Using RGD peptide obtained in the same manner as in Example 1 Example 5 RGD peptide obtained in the same manner as in Example 1 An oil phase and an aqueous phase were prepared using the following raw material compositions. Then, the water phase, which had also been heated to 80°C, was added to the oil phase which had been heated to 80'C, and the mixture was rapidly cooled while stirring uniformly to obtain skin milk.
組成
（油相） 配合量（ｗｔ％）流動パラフ
ィン ２０．００
セチルアルコール ５．００
ポリオキシエチレンソルビタン
モノオレート ５，００
（水相）
ＲＧＤペプチド
キサンタンガム
メチルパラベン
精製水 総量を１
０．０３
１．００
０．１０
００％とする残量
実施例６
実施例２と同様にして得たＲＧＤＳペプチドを用い、下
記のような原料組成にして油相と水相を調製した。そし
て、８０°Ｃに加熱した油相に同じく８０°Ｃに加熱し
た水相を加えて、均一に撹拌しながら速やかに冷却しス
キンクリームを得た。Composition (oil phase) Amount (wt%) Liquid paraffin 20.00 Cetyl alcohol 5.00 Polyoxyethylene sorbitan monooleate 5.00 (Aqueous phase) RGD peptide xanthan gum methylparaben Purified water Total amount 1 0.03 1.00 0 Remaining amount to be 1000% Example 6 Using the RGDS peptide obtained in the same manner as in Example 2, an oil phase and an aqueous phase were prepared with the following raw material compositions. Then, an aqueous phase also heated to 80°C was added to the oil phase heated to 80°C, and the mixture was quickly cooled while stirring uniformly to obtain a skin cream.
組成
（油相） 配合ｌ（ｗｔ％）ミリス
チン酸オクチルドデシル ３５．００セチルアルコール
５．００セチルパルミテート
２．００セスキステアリン酸ソルビタン ３．
００（水相）
ＲＧＤＳペプチド ０．０５カルボキシ
メチルセルロース ２．００ボオキシエチレンソル
ビクン
モノオレート（２０Ｅ、Ｏ，） ５．００メ
チルパラベン ０．１０精製水
総量を１００％とする残量比較例１
実施例１と同様にして得たＲＧＤペプチドを用い、下記
のような原料組成にしてこれらの成分を均一に混合する
ことによりスキンローションを得た。Composition (oil phase) Blend l (wt%) Octyldodecyl myristate 35.00 Cetyl alcohol 5.00 Cetyl palmitate
2.00 Sorbitan Sesquistearate 3.
00 (aqueous phase) RGDS peptide 0.05 Carboxymethyl cellulose 2.00 Boxyethylene sorbicun monooleate (20E, O,) 5.00 Methyl paraben 0.10 Purified water
Comparative Example 1 of Remaining Amount with Total Amount as 100% Using the RGD peptide obtained in the same manner as in Example 1, a skin lotion was obtained by uniformly mixing these ingredients with the following raw material composition.
組成 配合量（ｗｔ％）ＲＧＤ
ペプチド ０．０１精製水 総量を１
００％とする残量比較例２
実施例２と同様にして得たＲＧＤＳペプチドを用い、下
記のような原料組成にしてこれらの成分を均一に混合す
ることによりスキンローションを得た。Composition Amount (wt%) RGD
Peptide 0.01 Purified water Total amount 1
00% Remaining Amount Comparative Example 2 Using the RGDS peptide obtained in the same manner as in Example 2, a skin lotion was obtained by uniformly mixing these ingredients with the following raw material composition.
組成 配合量（ｗＬ％）ＲＧＤ
Ｓペプチド ０．０１精製水 総量を１
００％とする残量比較例３
下記のような原料組成を均一に混合することによりスキ
ンローションを得た。Composition Blend amount (wL%) RGD
S peptide 0.01 Purified water Total amount 1
Remaining amount as 00% Comparative Example 3 A skin lotion was obtained by uniformly mixing the following raw material composition.
組成 配合１（ｗｔ％）可溶性
コラーゲン ２．０精製水 総量を１
００％とする残量上記のようにして得られた６種類の実
施別品及び３種類の比較測高について、前記の手順に従
って各試験を行い評価した。その結果を第１表に示した
。Composition Blend 1 (wt%) Soluble collagen 2.0 Purified water Total amount 1
Remaining amount to be 00% The six types of experimental products and three types of comparative height measurements obtained as described above were subjected to each test and evaluated in accordance with the above-mentioned procedure. The results are shown in Table 1.
この表からも判るように、実施別品はいずれもＲＯＤペ
プチドやＲＧＤＳペプチドを単独で用いた比較例１．２
や水溶性高分子である可溶性コラーゲンを単独で用いた
比較例３よりも荒肌改善効果、角質改善効果及び実用試
験に極めて優れた効果を示した。また、比較例３で問題
となる経口安〔発明の効果］
以上に述べたように、本発明の皮膚化粧料は、ＲＣ，Ｄ
ペプチドまたはＲＧＤＳペプチドと水溶性高分子とが含
有されているため、これを用いると、肌荒れを起こすこ
となく肌の乾燥化、老化を防止することができる。しか
も、この化粧料は、色や匂いが経口的に変化することが
なく、長期間安心して使用することができるという利点
を有する。As can be seen from this table, Comparative Examples 1 and 2 in which ROD peptide and RGDS peptide were used alone
Compared with Comparative Example 3 in which soluble collagen, which is a water-soluble polymer, was used alone, it showed extremely superior effects on rough skin improvement, keratin improvement effects, and practical tests. In addition, oral safety, which is a problem in Comparative Example 3 [Effect of the invention] As described above, the skin cosmetic of the present invention has RC, D
Since it contains a peptide or RGDS peptide and a water-soluble polymer, it can prevent dryness and aging of the skin without causing rough skin. Furthermore, this cosmetic has the advantage that its color and odor do not change orally and can be used safely for a long period of time.
Claims (1)
ドＡｒｇ−Ｇｌｙ−Ａｓｐ−Ｓｅｒと水溶性高分子を含
有してなる皮膚化粧料Skin cosmetics containing tripeptide Arg-Gly-Asp or tetrapeptide Arg-Gly-Asp-Ser and water-soluble polymer
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP33378188A JPH02178207A (en) | 1988-12-28 | 1988-12-28 | Dermal cosmetic |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP33378188A JPH02178207A (en) | 1988-12-28 | 1988-12-28 | Dermal cosmetic |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH02178207A true JPH02178207A (en) | 1990-07-11 |
Family
ID=18269887
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP33378188A Pending JPH02178207A (en) | 1988-12-28 | 1988-12-28 | Dermal cosmetic |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH02178207A (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH04210611A (en) * | 1990-11-30 | 1992-07-31 | Shiseido Co Ltd | Dermatic agent composition for external use |
| US5492894A (en) * | 1991-03-21 | 1996-02-20 | The Procter & Gamble Company | Compositions for treating wrinkles comprising a peptide |
| FR2872040A1 (en) * | 2004-06-23 | 2005-12-30 | Centre Nat Rech Scient | COSMETIC USE OF AT LEAST ONE AC-N-SER-ASP-LYS-PRO NATURAL TETRAPEPTIC OR ONE OF ITS ANALOGUES AS AN ANTI-AGING AND RESTRUCTURING AGENT OF THE SKIN |
| ES2283212A1 (en) * | 2006-03-31 | 2007-10-16 | Lipotec S.A. | Synthetic peptides used for treating the skin and use thereof in cosmetic or dermopharmaceutical compositions |
| WO2008146116A2 (en) * | 2007-05-29 | 2008-12-04 | Labo Cosprophar Ag | Cosmetic composition with a lifting effect for sustaining relaxed skin tissues |
| JP2010077046A (en) * | 2008-09-25 | 2010-04-08 | Nikko Seiyaku Kk | Cosmetic for electroporation |
-
1988
- 1988-12-28 JP JP33378188A patent/JPH02178207A/en active Pending
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH04210611A (en) * | 1990-11-30 | 1992-07-31 | Shiseido Co Ltd | Dermatic agent composition for external use |
| JP2604643B2 (en) * | 1990-11-30 | 1997-04-30 | 株式会社資生堂 | Skin external preparation composition |
| US5492894A (en) * | 1991-03-21 | 1996-02-20 | The Procter & Gamble Company | Compositions for treating wrinkles comprising a peptide |
| FR2872040A1 (en) * | 2004-06-23 | 2005-12-30 | Centre Nat Rech Scient | COSMETIC USE OF AT LEAST ONE AC-N-SER-ASP-LYS-PRO NATURAL TETRAPEPTIC OR ONE OF ITS ANALOGUES AS AN ANTI-AGING AND RESTRUCTURING AGENT OF THE SKIN |
| WO2006008392A1 (en) * | 2004-06-23 | 2006-01-26 | Centre National De La Recherche Scientifique(Cnrs) | Cosmetic use of at least one type of natural ac-n-ser-asp-lys-pro tetrapeptide or one of the analogs thereof in the form of a skin antiaging and restructuring agent |
| JP2008503555A (en) * | 2004-06-23 | 2008-02-07 | サントル、ナショナール、ド、ラ、ルシェルシュ、シアンティフィク、（セーエヌエルエス） | Cosmetic use of at least one natural Ac-N-Ser-Asp-Lys-Pro tetrapeptide or one of its analogs as an anti-skin aging and remodeling agent |
| US8697652B2 (en) | 2004-06-23 | 2014-04-15 | Centre National De La Recherche Scientifique (Cnrs) | Cosmetic use of at least the natural tetrapeptide Ac-Ser-Asp-Lys-Pro or one of its analogs as a skin restructuring agent |
| ES2283212A1 (en) * | 2006-03-31 | 2007-10-16 | Lipotec S.A. | Synthetic peptides used for treating the skin and use thereof in cosmetic or dermopharmaceutical compositions |
| WO2007113356A3 (en) * | 2006-03-31 | 2012-12-20 | Lipotec S.A. | Synthetic peptides used for treating the skin and use thereof in cosmetic or dermopharmaceutical compositions |
| WO2008146116A2 (en) * | 2007-05-29 | 2008-12-04 | Labo Cosprophar Ag | Cosmetic composition with a lifting effect for sustaining relaxed skin tissues |
| WO2008146116A3 (en) * | 2007-05-29 | 2009-01-29 | Labo Cosprophar Ag | Cosmetic composition with a lifting effect for sustaining relaxed skin tissues |
| JP2010077046A (en) * | 2008-09-25 | 2010-04-08 | Nikko Seiyaku Kk | Cosmetic for electroporation |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5468475A (en) | Cosmetic composition with choline derivative | |
| KR101988675B1 (en) | Peptides useful in the treatment and/or care of the skin and/or mucous membranes and their use in cosmetic or pharmaceutical compositions | |
| JP2002524487A (en) | Use of a peptide for scarring, moisturizing and improving skin appearance as a cosmetic or dermatological agent during natural aging or hyperaging (sun dermatitis, contamination) | |
| EP0725083B1 (en) | Low-molecular-weight acetylated hyaluronic acid, emollient, and processes for producing and purifying the acid | |
| ES2566493T3 (en) | Synthetic peptides used for the treatment of the skin and their use in cosmetic or dermopharmaceutical compositions | |
| CA2692190C (en) | Novel compounds, use thereof in cosmetic and cosmeceutic applications, and compositions comprising same | |
| JPH04282304A (en) | Cosmetic composition | |
| JPH02178207A (en) | Dermal cosmetic | |
| JPH06157270A (en) | Cosmetic | |
| CN113271920B (en) | Peptides and compositions for cosmetic use | |
| JP2004067552A (en) | Collagen production promoter, and cosmetic containing the same | |
| JP3342050B2 (en) | Cosmetics | |
| JP2611956B2 (en) | Skin cosmetics | |
| JP2553474B2 (en) | Skin cosmetics | |
| JP4046426B2 (en) | Ceramide derivative and skin cosmetic containing the same | |
| JPH0383908A (en) | Skin cosmetic | |
| JP2511817B2 (en) | Skin cosmetics | |
| JPS62148414A (en) | Skin cosmetic | |
| JPH08217656A (en) | Cosmetic | |
| JPS63139104A (en) | Skin cosmetic | |
| WO2004080432A1 (en) | Composition for lip cosmetics | |
| JPS63159303A (en) | Skin cosmetic | |
| JPS62249912A (en) | Skin cosmetic | |
| JP3742133B2 (en) | Modified collagen and cosmetics | |
| JPH03240717A (en) | Skin cosmetic |